Insider Trades
News
seekingalpha.comKura Oncology, Inc. (KURA) Discusses Long-Term Results of Ziftomenib Combination Therapies in Newly Diagnosed and Relapsed/Refractory AML Transcriptseekingalpha.comJun 12
globenewswire.comKura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AMLglobenewswire.comJun 11
globenewswire.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 5
seekingalpha.comKura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for Darlifarnib Transcriptseekingalpha.comJun 4
globenewswire.comKura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategyglobenewswire.comJun 3